Skip to main content

Table 2 HRQoL utility values as per multi-attribute utility analysis

From: Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer

 

Goserelin

Chemotherapy

Age

42.6 ± 7.3

45.6 ± 6.5

Mean of SG

0.81 ± 0.17

0.78 ± 0.23

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us